{"name":"Zentalis Pharmaceuticals","slug":"zentalis","ticker":"ZNTL","exchange":"NASDAQ","domain":"zentalis.com","description":"Zentalis Pharmaceuticals is a clinical-stage biotech company focused on developing innovative oncology therapies. The company's pipeline includes several promising candidates, including ZN-c5, a potential treatment for various types of cancer. With a strong focus on precision medicine, Zentalis aims to bring new hope to patients with limited treatment options. As a relatively new player in the oncology space, Zentalis has significant growth potential.","hq":"New York, NY","founded":0,"employees":"","ceo":"Anthony Sun, M.D.","sector":"Oncology / Clinical-Stage Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$220M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":107295000,"netIncome":-137060000,"cash":35995000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Zentalis reported a net loss of $43.4 million for the fourth quarter and $143.4 million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-12-18","type":"deal","headline":"Zentalis Pharmaceuticals Announces Collaboration with Merck KGaA to Develop ZN-c5 in Combination with Merck's KEYTRUDA","summary":"Zentalis and Merck KGaA announced a collaboration to develop ZN-c5 in combination with KEYTRUDA for the treatment of various types of cancer.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"trial","headline":"Zentalis Pharmaceuticals Announces Positive Interim Results from Phase 1/2 Clinical Trial of ZN-c5","summary":"Zentalis announced positive interim results from a Phase 1/2 clinical trial of ZN-c5, demonstrating encouraging efficacy and safety data.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOdWxiZGVjbTJPX3pSdEE3NjZ6SzFEaVR3V0Qzd0hBRWd4Mk9HMHdoUFhyQXp3cy1PSV84VENwZXZieW9HOXEyVTcxMVJZV3NJTzhMc1c1YVlDOFg0R3J4dkVvTGhXM2RFM0dzYVpCcU1FUHMyYXg5V0U1dUtucVNhZU43cHRGYTdEX1FEYnBUcTFSVnZLS201UkllUXRFRjhlZ1FkU3NsVEU1bnc?oc=5","date":"2026-03-18","type":"earnings","source":"Defense World","summary":"Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Wednesday - Defense World","headline":"Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Wednesday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOb2tUMXlhb1NpdXRla2hrWG5uV2N2TnJ5M0NzTUZjVmRfMllKdF9NNzNpTTJDWGE5N1ZDVWQ4MnlnQmUwRXNic1FkbU1jbm9od0FTR0RiQV8wdUZ2eDBQdXRIM2EwLVVGSXhlUFpWTGZDQXAwa2E4azJyaEVRWGhIRC1nTmw1dnVrTG5xelpIYUw3eE9wTkpzOGFjV1hpSm8tLWI5cUFTOFZ2TExwN2hZ?oc=5","date":"2026-02-10","type":"pipeline","source":"Investing.com","summary":"Zentalis Pharma CMO Bruns sells $7998 in stock - Investing.com","headline":"Zentalis Pharma CMO Bruns sells $7998 in stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNR09KQ0doUk13TTBhTldQeUpvbUlvSG9aWlpVTHFocllnX3VaU29BUE9YQ0V4Y29Ua2tCN1NFOXZSZDJmeHZVaGFjS0JJU0QyNWFuLVhSS01MUE1HaGFxeXJOemxBcGxZbGlyNThKVHNMTW9NOEZwRjlCT2Z1TWQtQW9jZk9hSXBNSm9JMWhSNVpZdkxmMXhTd0hwNU9kbm9HT2x0OVA1Umtic2V6bi03cW5SUQ?oc=5","date":"2026-02-10","type":"pipeline","source":"Investing.com","summary":"Zentalis Pharma CEO Eastland sells $21k in shares - Investing.com","headline":"Zentalis Pharma CEO Eastland sells $21k in shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNOEJTOWpWNHdwdWhpeG1zUkd2dks2c21LUU9VdTQ4azJvMGFMVmd0WjJwQ0VES2lpbF9ILVQtV3FYMHowbzhmWUZrSTdHNl9LcWRQTG9oUGVrbi00VUo2blBmWm5UQ0U2NGZvRUtvVUxEVlZiSkQ3WHNvaUJaeHhGS1ZYcWxLbDZDTHc?oc=5","date":"2026-01-11","type":"pipeline","source":"timothysykes.com","summary":"Zentalis Pharma Advances Stir Market as Azenosertib Program Strengthens - timothysykes.com","headline":"Zentalis Pharma Advances Stir Market as Azenosertib Program Strengthens","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQVlJpTm91T3Y3V0Y1eDlueXg0UzY3MWhBdnRpTlRJVWZaNjBEUzhLYlZGUWFILXdNTGZpejA1UE9NUTdaYUVFOXhCTFJscWVpSDVZazRuNmJVZjg1TmVobE1JdWVRWjAyMGNWLUtGR2ZlclZuNncyV1RzZW5xQ1lMeHBKeWtndw?oc=5","date":"2026-01-10","type":"pipeline","source":"StocksToTrade","summary":"Zentalis Pharmaceuticals Surges After Promising Azenosertib Developments - StocksToTrade","headline":"Zentalis Pharmaceuticals Surges After Promising Azenosertib Developments","sentiment":"neutral"},{"date":"2026-01-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-07","type":"pipeline","source":"simplywall.st","summary":"Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Shares Bounce 28% But Its Business Still Trails The Industry - simplywall.st","headline":"Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Shares Bounce 28% But Its Business Still Trails The Industry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxNVFVuUVNlbWhOa0lMOFNtSE9PRTFLRXg0OUVjRkJjNklRczJvM2NtWXVxU3FmZDQ0cU1VckZ0Y21yYmgyYURNbmlyTEYwWnhsaGZpOWUwVE5pZTlTMXNSYzlEbWY3N1VBT2p4MTJ4V0UyX2t3RHFjY2NxOXBtSWpBZWFIT2NUQkNIMzlhaXk2QnR2Rk5qRDlfTnRrZDdBc2NFeWNzbjMxNUlydkZCYVI0Y2RUMEl5dXRkNzhoQUw3c0JhT2RZOGhRbGtTQ3RYdml1OXItLTFCT3JBR0NlTndnZjRDZTN4THJVYXdBYXR3U2k1UnNmX2YwX21WWjNpcE1HNkpSX01WM0h4dEdJVUpDMzI4QWVQUF8tOGZYZ3Z4OWpaQktRQ1pxdjNRQkpxczdWTG1EbXNmS3YzVUhpNXZDSmhaUGw?oc=5","date":"2026-01-06","type":"pipeline","source":"globenewswire.com","summary":"Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 - globenewswire.com","headline":"Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenoserti","sentiment":"neutral"},{"date":"2025-12-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQdVZ5ckY3NnBDbGZSSV82RmllNFhnUVJLZUFfY0hOSmU0TVVpa0tqNTVDVVNkWlJFX25MLUZHaHFtaFR0aXZrRzlOQ0s1dTBPTTdFS01paUVFakZVbExRbGRaaGlDZTZpN2ppZ2hvNUJVeGxBSjZYMTF4eDR5dHF2VEk0bW9VdkFYSTRZRGJ6MDRxY29DWU9rZ0JHMDZJYVZCM1RaYjNKaTdIWmFMNVdYbw?oc=5","date":"2025-11-18","type":"regulatory","source":"Seeking Alpha","summary":"Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval (ZNTL) - Seeking Alpha","headline":"Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval (ZNTL)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPaVdRSTViV25GbmdVNXVUelRwNFZXLTVhRm1WeHFWX3RRRGxqVkhsTDVTbzc5SElDNXRZZFdja1JHM25wQ3RnbVpBZk5zU1piSXV0ZGhFVTlqTjFLaUpHRTFaRmxzNzh2aHNqMEsxZFpmb1VtS2NKMnc1T19oMDk2QmdwSS0wcnM2ZUdnMG1ERUU4dWIwb2Z5MDVfX2VWRmZJUkd1SkxtZGZ0MHNCM0JLQnU1aw?oc=5","date":"2025-11-12","type":"pipeline","source":"GuruFocus","summary":"ZNTL Stock Update: Morgan Stanley Lowers Price Target by 50% | Z - GuruFocus","headline":"ZNTL Stock Update: Morgan Stanley Lowers Price Target by 50% | Z","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNbjVyR3pQeTdDeVFiU1FLSDRpVml5a2xid25sR0x3bk1lWGtEZEY3c0k4ZHVyeDdsWG1iQzVMNzVVdllNNTBzTjJkZEphTUFQSDBQM0tSdEdLbmdWUnAwVF9WbjViWWstWVRxYWVGRkRvU2JaemRidURNTllNYXpib3l5MFQ?oc=5","date":"2025-06-26","type":"pipeline","source":"Yahoo Finance","summary":"Here's Why We're Watching Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation - Yahoo Finance","headline":"Here's Why We're Watching Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBnb1dNSlRZTFVnand6LXo0Z0hxOXEwLVVyN3ZnWGczLU5kV2xsdUdOeE9FbjQ5bkJ5MDNxaE1rbkpHR2ZFenRER1ctdkQ3cG1UdE1z?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"ZNTL Stock Price, News & Analysis - Stock Titan","headline":"ZNTL Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Clovis Oncology","AstraZeneca","Merck & Co."],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":0,"period":"2025-12-31"},{"value":67425000,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"},{"value":0,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":107295000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-137060000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":35995000,"cashHistory":[],"totalAssets":288967000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}